@article {Kim2021.03.29.21253871, author = {Jung Ho Kim and Jeong Hoon Hong and Yoon-La Choi and Ji Ae Lee and Mi-kyoung Seo and Mi-Sook Lee and Sung Bin An and Min Jung Sung and Nam-Yun Cho and Sung-Su Kim and Young Kee Shin and Sangwoo Kim and Gyeong Hoon Kang}, title = {NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions}, elocation-id = {2021.03.29.21253871}, year = {2021}, doi = {10.1101/2021.03.29.21253871}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background NTRK fusions are emerging tissue-agnostic drug targets in malignancies including colorectal cancers (CRCs), but their detailed landscape in the context of various colorectal carcinogenesis pathways remains to be investigated.Methods Pan-TRK expression was assessed by immunohistochemistry in retrospectively collected colorectal epithelial tumor tissues, including 441 CRCs (133 microsatellite instability-high (MSI-high) and 308 microsatellite stable (MSS)) and 565 premalignant colorectal lesions (300 serrated lesions and 265 conventional adenomas). TRK-positive cases were subjected to next-generation sequencing and/or fluorescence in situ hybridization to confirm NTRK rearrangements.Results TRK positivity was not observed in any of the MSS CRCs, conventional adenomas, traditional serrated adenomas, or hyperplastic polyps, whereas TRK positivity was observed in 11 of 58 (19\%) sporadic MSI-high CRCs, 4 of 23 (17\%) sessile serrated lesions with dysplasia (SSLDs), and 5 of 132 (4\%) SSLs. The 11 TRK-positive MSI-high CRCs commonly harbored CpG island methylator phenotype-high (CIMP-high), MLH1 methylation, KRAS/BRAF wild-type, and NTRK1 or NTRK3 fusion (TPM3-NTRK1, TPR-NTRK1, LMNA-NTRK1, SFPQ-NTRK1, ETV6-NTRK3, or EML4-NTRK3). Both NTRK1 or NTRK3 rearrangement and KRAS/BRAF wild-type were detected in all nine TRK-positive SSL(D)s, seven of which demonstrated MSS and/or CIMP-low. TRK overexpression and early dysplastic changes are occasionally co-localized in the crypt base area of SSLs. Age-related occurrence patterns suggest that the progression interval from NTRK-rearranged SSLs to CRCs may be shorter than from BRAF-mutated SSLs to CRCs.Conclusion NTRK-rearranged colorectal tumors develop exclusively through the serrated neoplasia pathway and can be initiated from non-dysplastic SSLs without KRAS/BRAF mutations prior to full occurrence of MSI-high/CIMP-high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the SNUH Research Fund (04-2016-0680 to JHK; 04-2020-0550 to JHK), the National Research Foundation of Korea grants funded by the Korea government (Ministry of Science and ICT) (NRF-2016R1C1B2010627 to JHK; NRF-2019R1F1A1059535 to JHK; NRF-2016R1A5A2945889 to Y-LC; NRF-2019R1A2B5B02069979 to Y-LC), a grant from the National OncoVenture project through the Korea Health Industry Development Institute (KHIDI) funded by the Korea government (Ministry of Health \& Welfare) (HI17C2196040021 to YKS), and a grant from the Korea Health Technology R\&D Project through KHIDI funded by the Korea government (Ministry of Health \& Welfare) (HI14C1324 to SK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Seoul National University Hospital (IRB No. 1804-036-935; 1804-109-939)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw RNA sequencing data for the detection of NTRK fusions were deposited in the SRA/BioProject database (accession number: PRJNA715305; URL: http://www.ncbi.nlm.nih.gov/bioproject/715305). All other data are available from the corresponding authors (JHK or Y-LC) upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/03/30/2021.03.29.21253871}, eprint = {https://www.medrxiv.org/content/early/2021/03/30/2021.03.29.21253871.full.pdf}, journal = {medRxiv} }